1036395-80-8

Basic information

• Product Name: 3-[3-Chloro-4-(trifluoromethyl)phenyl]propionicacid
• Synonyms: 3-[3-Chloro-4-(trifluoromethyl)phenyl]propionicacid
• CAS NO: 1036395-80-8
• Molecular Weight: 252.621
• Mol File: 1036395-80-8.mol

Chemical Properties

• CAS DataBase Reference: 3-[3-Chloro-4-(trifluoromethyl)phenyl]propionicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[3-Chloro-4-(trifluoromethyl)phenyl]propionicacid(1036395-80-8)
• EPA Substance Registry System: 3-[3-Chloro-4-(trifluoromethyl)phenyl]propionicacid(1036395-80-8)

Safety Data

• Hazardous Substances Data: 1036395-80-8(Hazardous Substances Data)

Usage

Class

Carboxylic acids

Physical properties

White crystalline powder, insoluble in water

Uses

Pharmaceutical intermediate, raw material in drug synthesis, production of pesticides, fragrances, and other organic compounds

Potential applications

Medicinal chemistry, drug development, due to structural properties and biological activity

Upstream product

• 467435-07-0 4-bromo-2-chloro-1-(trifluoromethyl)benzene 
• 155626-44-1 ethyl 3-(3-chloro-4-(trifluoromethyl)phenyl)acrylate 
• 1261674-37-6 ethyl 3-(3-chloro-4-(trifluoromethyl)phenyl)propanoate 
• 83279-38-3 3-chloro-4-(trifluoromethyl)benzaldehyde 
• 1092460-80-4 C₁₀H₆ClF₃O₂ 

Downstream Products

• 1036395-95-5 3-(3-chloro-4-trifluoromethylphenyl)propan-1-ol 
• 1036396-40-3 3-(3-chloro-4-trifluoromethylphenyl)propionaldehyde 

Relevant articles and documents

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2

Replacement of the dimethoxyphenyl moiety in the core skeleton of almorexant by appropriately substituted imidazoles afforded novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as potent dual orexin receptor antagonists. We describe in th

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.